The Executive Leadership in Health Care program is targeted to rising women at the equivalent of the associate professor level who are established experts in their domain. Candidates will have a track record of achievement in clinical program development (or other institutional-level activities that mark them as appropriate) and have aspirations to lead at the executive level in the next five years.

ELH is a hybrid year-long program with three weeklong in-person sessions and a longitudinal action project designed to advance the fellow’s standing at their institution. Sessions incorporate traditional didactics, simulation and group work. Fellows receive structured coaching from certified coaches and are assigned to a learning community.

Candidates should be at least seven years out of training, with an MD or MD-equivalent degree, with:

- Program-level leadership
- Institutional level responsibilities (operational or strategic management)
- Aspirations to executive-level health system roles (executive leadership, chief medical officer, chief quality officer)

ELH fellows will have the unique opportunity to work alongside their ELAM colleagues during certain curricular threads.

The ELH program is a track of the Executive Leadership in Academic Medicine® (ELAM) fellowship that focuses more on health care operations and less on research than the traditional ELAM track.
As an ELH fellow and graduate, you will have the power of the ELAM network to support you — more than 1,300 alumnae in leadership positions at 300 institutions in North America and beyond.

PROGRAM OBJECTIVES

Upon graduation from ELH fellows will be able to:

• Use strategic approaches to financial and resource management that enhance the missions of their organizations.
• Enhance their leadership behaviors to effectively address strategic, operational and relational challenges.
• Lead and manage change initiatives within complex and dynamic organizations.
• Collaborate with a variety of stakeholders in order to build a diverse community of leadership practice that supports personal, professional and organizational effectiveness.

The ELAM Program, Drexel University College of Medicine  |  2900 W. Queen Lane, Philadelphia, PA 19129
P: 215.991.8240  •  F: 215.991.8171  •  E: elamprogram@drexel.edu  •  W: drexel.edu/elam

PROGRAM SCHEDULE

JUN 1 – SEP 12, 2024
Complete self-assessments, assigned readings, and online assignments
SEP 13 – 20, 2024
Attend Session 1 - Philadelphia
SEP 21, 2024 – JAN 24, 2025
Work on group and independent projects
JAN 25 – 30, 2025
Attend Session 2 - Philadelphia

JAN 31 – APR 25, 2025
Work on group and independent projects
APR 26 – May 1, 2025
Attend Session 3 - Philadelphia
(April 30 - May 1 with deans, institutional sponsors and guests. Leaders Forum on April 30, Graduation on May 1)

ELH at ELAM’s program fee is $16,400, which covers in-person dates, distance learning activities throughout the fellowship year, course materials, faculty/facilitators, conference site expenses, continuing education fees, special events and most meals for the fellows. In addition to the program fee, the fellow or her institution is responsible for travel and lodging during the sessions, and some meals.

Application to the program for the 2024–2025 fellowship year opens online (drexel.edu/elam) on October 1, 2023. Applications are due by December 1, 2023. Nominations and recommendations are due by December 15, 2023.

FACULTY DISCLOSURE STATEMENT: It is the policy of Drexel University College of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. All individuals in a position to control content at continuing medical education activities are required to disclose to the audience any relevant financial relationships with ineligible companies (which is any entity whose primary business is producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients). Any conflicts of interest must be mitigated prior to the presentation and announced to the audience. In addition, speakers are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation.